Stocksigma LogoStocksigma Logo

Fredun Pharmaceuticals Faces Preferential Issue Fund Utilization Deviations Flagged by CARE Ratings

CARE Ratings flagged a 10–25% deviation in Fredun Pharmaceuticals' ₹149.50 cr preferential issue proceeds utilization for the quarter ended 30th Sep'26

Fredun Pharmaceuticals Faces Preferential Issue Fund Utilization Deviations Flagged by CARE Ratings

Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 14 Nov 2026, 9:02 pm

Fredun Pharmaceuticals Faces Preferential Issue Fund Utilization Deviations Flagged by CARE Ratings CARE Ratings flagged a 10–25% deviation in Fredun Pharmaceuticals' ₹149.50 cr preferential issue proceeds utilization for the quarter ended 30th Sep'26. Out of ₹128.78 cr received, the monitoring agency reported total utilization at ₹101.34 cr versus ₹97.56 cr claimed by management. Key concerns include non-traceability of source funds due to opening unutilized balance discrepancies in Q2FY27 (₹34.43 cr vs ₹21.47 cr reported in Q1FY27), comingling of funds, and parking proceeds in debit-balance Cash Credit accounts. Management maintains funds were used strictly for approved business objects without diversion.

Original exchange filing (PDF)

More announcements from Fredun Pharmaceuticals Ltd

All Fredun Pharmaceuticals Ltd announcements